The company said that data from its Phase III trial in severe Covid-19 showed similar efficacy for patients receiving the drug for five and 10 days, though the study lacks a control arm. It also said it received word that an NIAID-sponsored study of the drug was positive, but data have not been released.

LEAVE A REPLY

Please enter your comment!
Please enter your name here